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CASE REPORT
A 28-year-old woman presented to the emergency 
unit with a 3-week history of fever, shortness of 
breath, cough (productive of whitish, frothy 
sputum) and bilateral leg swelling. There was 
associated history of orthopnoea, paroxysmal 
nocturnal dyspnoea, easy fatigability and 
palpitations. On examination, she was acutely ill-
o
looking, febrile (37.5 C) and had bilateral pitting 
pedal oedema up to her ankles. She also had grade 4 
finger clubbing. Her pulse rate was 104 beats per 
minute and blood pressure was 90/60 mmHg. Her 
praecordium was hyperactive with her apex located 
that the 6  left intercostal space, anterior axillary line. 
Her jugular venous pressure was raised and heart 
st nd rdsounds were 1 , 2  and 3  with grade 3/6 mitral 
regurgitation and tricuspid regurgitation murmurs. 
Her liver and spleen were palpable 8 cm and 2 cm 
below the right and left costal margins respectively. 
She had ascites demonstrable by a fluid thrill. She 
was dyspnoeic with a respiratory rate of 40 cycles 
per minute. She also had bibasal crepitations. 
Echocardiography done showed moderate-to-
severe anterior mitral valve leaflet (AMVL) and 
posterior mitral valve leaflet (PMVL) sclerosis with 
the PMVL tethered to the posterior wall. Severe 
eccentric mitral regurgitation (MR) was also 
observed. Moderate-to-coarse vegetations were 
seen on the AMVL and PMVL, being flung with 
evidence of imminent dislodgement. Ongoing 
moderate tachycardia was also observed. 
Electrocardiography done showed sinus tachycardia 
with low voltages in chest leads. Samples taken for 
blood cultures returned negative (patient had 
already received antibiotics prior to presentation). 
An assessment of biventricular heart failure and 
infective endocarditis with background rheumatic 
valvular heart disease (severe MR) was made. She 
was placed on diuretics, digoxin and also received a 
course of intravenous antibiotics. Her clinical status 
improved significantly while on admission and a 
repeat echocardiography done showed a marked 
reduction in the size of the vegetations on the mitral 
valve. She was subsequently discharged and is 
currently on follow-up at the Cardiology Clinic. 
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ABSTRACT
Endocarditis is  of the inner layer of the , the . It usually involves the 
. Other structures that may be involved include the , the , the 
mural endocardium or the surfaces of intracardiac devices. Infective endocarditis is a form of endocarditis 
caused by infectious agents, which are usually bacterial (other organisms can also be responsible). Before 
the age of modern antibiotics it was almost universally fatal. Although the epidemiology of infective 
endocarditis has changed over the last 50 years, with rheumatic heart disease becoming less common and 
degenerative valve disease more frequent, its incidence and associated mortality have remained relatively 
constant.
Keywords: Infective endocarditis, cardiology, infectious diseases, heart valves
inflammation heart endocardium heart 
valves interventricular septum chordae tendineae
Figure 1: Two-dimensional echocardiography 
(parasternal long axis view) showing sclerosis of the 
anterior and posterior mitral valve leaflets with the 
posterior mitral valve leaflet tethered to the posterior 
wall. Moderate-to-coarse vegetations (outlined) 
observed on the anterior mitral valve leaflet.
DISCUSSION
Infective endocarditis (IE) is defined as an infection 
of the endocardial surface of the heart which may 
include one or more heart valves, the mural 
endocardium or a septal defect. Its intracardiac 
effects include severe valvular insufficiency, which 
may lead to intractable congestive heart failure and 
myocardial abscesses. If left untreated, IE is 
generally fatal. Before the pandemic of human 
immunodeficiency virus (HIV) infection, IE was the 
syndrome for which the expertise of infectious 
diseases physicians was almost universally 
requested. IE has the proclivity to cause 
complications both at the cardiac valve site and at 
extracardiac locations that can predispose affected 
patients to serious morbidity and mortality.
The global burden of disease due to IE is largely 
unknown. Much of the world's population lives in 
developing countries, where many people do not 
have routine access to advanced medical care. In 
addition, in most of these countries, no 
infrastructure exists on either a local or countrywide 
level for disease reporting. In a study published in 
1976 by Falase et al., 90 cases of IE were seen over a 
10-year-period at the University College Hospital, 
Ibadan. Peak incidence was reported to be in the 
third decade and rheumatic heart disease was the 
commonest pre-existing lesion in 59 cases with 
subacute endocarditis. In most cases, the source of 
infection was not known. In 41 of the 90 cases 
(44%), the diagnosis was made only at autopsy. The 
bacterial isolation rate was low, the commonest 
organisms being staphylococci, streptococci, 
micrococci and gram-negative bacilli. The overall 
mortality was 70%.
In developed countries, the epidemiology of IE has 
changed over the last 50 years, with rheumatic heart 
disease becoming less common and degenerative 
valve disease more frequent. Annual incidence is 4 - 
10 per 100 000 population and it is slightly more 
common in men. Nearly 75% of cases occur in the 
2nd, 3rd and 4th decades of life with peak incidence 
in the 3rd decade. The mortality of IE was 100% 
before the advent of antibiotics. In developed 
countries it is now reduced to around 30%. Autopsy 
incidence of IE (over 50 years) has been reviewed in 
a study published in 1978 by Mehta et al. 185 cases 
were recorded in a total of 39,931 autopsies giving 
an average incidence of 0.46%.
Contributing factors to the incidence of IE include 
increased prevalence of degenerative heart disease 
and increased use of invasive medical procedures. 
The majority of cases occur in those with 
predisposing identifiable cardiac structural 
abnormalities (congenital or acquired) or those with 
recognized risk factors of the disease, such as 
injection drug use (IDU), indwelling catheters, poor 
dental hygiene or infection with HIV. For IDUs, the 
estimated risk is 2 - 5% per year. It is generally on the 
right side of the heart and the tricuspid valve is 
affected in the vast majority of cases. Prosthetic 
valve IE (PVE) occurs in 3 - 6% of prosthetic valve 
recipients. The risk is highest in the first 6 months 
and then declines to 0.2 – 0.4% per year.
The mitral valve is the commonest site of pre-
dilection (as seen in the index case) irrespective of 
the aetiologic agent. The aortic valve is also 
commonly involved. Tricuspid valve involvement is 
rare but has been on the increase in recent years. It is 
however particularly common in drug addicts 
(IDUs). The commonest symptom of IE is fever 
o(usually more than 38 C). This is seen in about 80 – 
95% of patients. It may however be absent in elderly 
patients, patients on antibiotics or antipyretics, those 
with congestive cardiac failure or renal failure. 
Other features are: chills (40%), weakness (40%), 
dyspnoea (40%), anorexia (25%), cough (25%), 
malaise (25%), skin lesions (20%), nausea/vomiting 
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(10 – 20%), headache (20%), stroke (10 – 20%), 
chest pain (5 – 15%), abdominal pain (5 – 15%) and 
back pain (5 – 10%). The commonest signs are heart 
murmurs (85%), petechiae (20 – 40%), 
splenomegaly (20 – 57%) and embolic phenomena 
(>50%). A change in mental status may occur in 10 – 
15% of patients. This may be due to embolic stroke.
The main modalities of diagnosis of IE are blood 
cultures and echocardiography. The most popular 
diagnostic criteria used are the modified Duke 
criteria. Generally speaking, the diagnosis of IE 
based on these criteria are: (a) pathologic criteria 
(microorganisms demonstrated by culture or 
histology from lesions) and (b) clinical criteria 
(presence of two major criteria; one major and three 
minor criteria or five minor criteria). The treatment 
goals for IE are eradication of the microorganism 
responsible and resolution of any intra- and 
extracardiac infectious complications. The first is 
usually achieved with prompt intravenous antibiotic 
therapy directed at the causative agent, while the 
second often requires surgical intervention.
On suspicion of IE, patient should be started 
empirically on antibiotics. In a patient with an 
uncomplicated history, a popular regime is 
ceftriaxone with gentamicin. Definitive antibiotic 
treatment should be based on culture and sensitivity 
results. In general, antibiotics need to be continued 
for 4 to 6 weeks. The antibiotic therapeutic regime 
chosen depends on the type of valve involved 
(native or prosthetic), time between prosthetic valve 
implantation and infection (more or less than a year) 
and the aetiological agent, when identified. Around 
half of cases of IE are treated surgically due to 
serious complications. While this option should be 
considered in the active phase of the disease to 
prevent progression of heart failure, irreversible 
structural damage and systemic embolism, this 
phase is also associated with higher operative risk. 
Current indications for surgical treatment are: (1) 
refractory heart failure directly related to valve 
dysfunction; (2) uncontrolled infection; and (3) 
prevention of embolic phenomena. The risk of 
embolism is high (20 - 50%) in patients with IE, 
although it decreases rapidly following institution of 
directed antibiotic therapy, particularly after two 
weeks. There is a small role for extracardiac surgery 
in the treatment of neurological complications 
which may happen occasionally (e.g. ruptured 
mycotic aneurysm). The overall in-hospital 
mortality rate of IE is approximately 45%. The 
protean nature of IE, the latency of the associated 
cardiac symptoms and its close simulation of other 
disorders combine to render the detection of IE 
peculiarly difficult. A very high index of suspicion is 
therefore essential because this disease, if left 
untreated, is always fatal.
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